Tuesday, June 16, 2020 4:00:29 PM
I believe there will be a partnership between BP and NWBO. Don't know when or how much $$$ will be involved. But, without any doubt, I can say that if the tld is what we suspect (or as Anders2211 says, turn out to be "superb"), owning NWBO stock will be THE investment of our life time.
PB will have to partner with nwbo as a DCVax-L combo would increase the effectiveness of PB's most profitable products. Without DCVax-L their product(s) could be rendered obsolete. For someone to suggest that PB would not partner with NWBO until after approval is asinine, particularly when there appears to be some coordination between Merck and NWBO already (i.e. Duffy's temporary assignment at NWBO just prior to the completion of the p3 trial SAP). Likewise to suggest that NWBO's MC will be around $5/$6 billion even after approval is a bit crazy too no matter how one goes about determining mC value for NWBO.
We are in agreement, although I don't think it will 5-10 years for NWBO's market cap to grow way beyond $6 billion even if it rejects a buyout or giving significant control to BP in a partnership.
But what do I know....
PB will have to partner with nwbo as a DCVax-L combo would increase the effectiveness of PB's most profitable products. Without DCVax-L their product(s) could be rendered obsolete. For someone to suggest that PB would not partner with NWBO until after approval is asinine, particularly when there appears to be some coordination between Merck and NWBO already (i.e. Duffy's temporary assignment at NWBO just prior to the completion of the p3 trial SAP). Likewise to suggest that NWBO's MC will be around $5/$6 billion even after approval is a bit crazy too no matter how one goes about determining mC value for NWBO.
We are in agreement, although I don't think it will 5-10 years for NWBO's market cap to grow way beyond $6 billion even if it rejects a buyout or giving significant control to BP in a partnership.
But what do I know....
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
